BG107520A - Таблетка, получена чрез директно компримиране, съдържаща като активен ингрaдиент 4-амино-1-хидроксибутилиден -1,1-бисфосфонова киселина - Google Patents

Таблетка, получена чрез директно компримиране, съдържаща като активен ингрaдиент 4-амино-1-хидроксибутилиден -1,1-бисфосфонова киселина Download PDF

Info

Publication number: BG107520A
Authority: BG; Bulgaria
Prior art keywords: tablet; diluent; lactose; mannitol; microcrystalline cellulose
Prior art date: 2000-07-11

Application number

BG107520A

Other languages

Bulgarian (bg)

English (en)

Inventor

Dagmar Jasprova

Original Assignee

Zentiva, A.S.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2003-02-04

Publication date

2003-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5471285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107520(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-04 Application filed by Zentiva, A.S. filed Critical Zentiva, A.S.

2003-06-30 Publication of BG107520A publication Critical patent/BG107520A/bg

Links

239000004480 active ingredient Substances 0.000 title claims abstract description 23
238000007907 direct compression Methods 0.000 title claims abstract description 19
239000002253 acid Substances 0.000 title claims abstract description 18
239000003085 diluting agent Substances 0.000 claims abstract description 55
239000008101 lactose Substances 0.000 claims abstract description 43
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 42
239000002706 dry binder Substances 0.000 claims abstract description 13
239000000314 lubricant Substances 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 6
239000000203 mixture Substances 0.000 claims description 57
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 41
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 41
239000008108 microcrystalline cellulose Substances 0.000 claims description 41
229940016286 microcrystalline cellulose Drugs 0.000 claims description 41
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 36
229930195725 Mannitol Natural products 0.000 claims description 36
239000000594 mannitol Substances 0.000 claims description 36
235000010355 mannitol Nutrition 0.000 claims description 36
238000002360 preparation method Methods 0.000 claims description 32
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 11
235000019700 dicalcium phosphate Nutrition 0.000 claims description 11
229920002678 cellulose Polymers 0.000 claims description 10
239000001913 cellulose Substances 0.000 claims description 10
235000010980 cellulose Nutrition 0.000 claims description 9
239000007884 disintegrant Substances 0.000 claims description 9
229920000881 Modified starch Polymers 0.000 claims description 6
235000019426 modified starch Nutrition 0.000 claims description 5
229910019142 PO4 Inorganic materials 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
235000021317 phosphate Nutrition 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
150000001342 alkaline earth metals Chemical class 0.000 claims description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 abstract description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 43
229960001375 lactose Drugs 0.000 description 41
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 32
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 29
239000000047 product Substances 0.000 description 27
238000007906 compression Methods 0.000 description 25
238000012360 testing method Methods 0.000 description 24
230000006835 compression Effects 0.000 description 23
238000000034 method Methods 0.000 description 20
229960004343 alendronic acid Drugs 0.000 description 19
235000019359 magnesium stearate Nutrition 0.000 description 14
229940062527 alendronate Drugs 0.000 description 12
239000000126 substance Substances 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 10
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
229910052749 magnesium Inorganic materials 0.000 description 9
239000011777 magnesium Substances 0.000 description 9
230000008569 process Effects 0.000 description 9
229920002261 Corn starch Polymers 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
240000008042 Zea mays Species 0.000 description 8
235000002017 Zea mays subsp mays Nutrition 0.000 description 8
230000000694 effects Effects 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
229940127554 medical product Drugs 0.000 description 7
238000002156 mixing Methods 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
239000008107 starch Substances 0.000 description 7
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
235000005822 corn Nutrition 0.000 description 6
239000008120 corn starch Substances 0.000 description 6
229940099112 cornstarch Drugs 0.000 description 6
238000009472 formulation Methods 0.000 description 6
238000005469 granulation Methods 0.000 description 6
230000003179 granulation Effects 0.000 description 6
230000002411 adverse Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 5
238000004448 titration Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
238000005550 wet granulation Methods 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
238000005457 optimization Methods 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229960001855 mannitol Drugs 0.000 description 3
238000003860 storage Methods 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229960004977 anhydrous lactose Drugs 0.000 description 2
-1 calcium hydrogen Chemical class 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940057948 magnesium stearate Drugs 0.000 description 2
235000009973 maize Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000012552 review Methods 0.000 description 2
238000013112 stability test Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010007027 Calculus urinary Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101710081880 Glycylpeptide N-tetradecanoyltransferase 1 Proteins 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000008041 oiling agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
208000008281 urolithiasis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG107520A 2000-07-11 2003-02-04 Таблетка, получена чрез директно компримиране, съдържаща като активен ингрaдиент 4-амино-1-хидроксибутилиден -1,1-бисфосфонова киселина BG107520A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CZ20002567A CZ20002567A3 (cs)	2000-07-11	2000-07-11	Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
PCT/CZ2001/000037 WO2002003963A1 (fr)	2000-07-11	2001-06-29	Comprime obtenu par compression directe et renfermant de l'acide 4-amino-1-hydroxybutylidene-1,1-biphosphonique en tant qu'ingredient actif

Publications (1)

Publication Number	Publication Date
BG107520A true BG107520A (bg)	2003-06-30

Family

ID=5471285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107520A BG107520A (bg)	2000-07-11	2003-02-04	Таблетка, получена чрез директно компримиране, съдържаща като активен ингрaдиент 4-амино-1-хидроксибутилиден -1,1-бисфосфонова киселина

Country Status (17)

Country	Link
US (1)	US7198802B2 (fr)
EP (1)	EP1299088B1 (fr)
AT (1)	ATE331502T1 (fr)
AU (1)	AU2001270454A1 (fr)
BG (1)	BG107520A (fr)
CA (1)	CA2415630A1 (fr)
CZ (1)	CZ20002567A3 (fr)
DE (1)	DE60121166D1 (fr)
EE (1)	EE200300017A (fr)
HR (1)	HRP20020735A2 (fr)
HU (1)	HUP0301072A3 (fr)
PL (1)	PL360872A1 (fr)
RU (1)	RU2279273C2 (fr)
SK (1)	SK283249B6 (fr)
UA (1)	UA73784C2 (fr)
WO (1)	WO2002003963A1 (fr)
YU (1)	YU77702A (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6827718B2 (en)	2001-08-14	2004-12-07	Scimed Life Systems, Inc.	Method of and apparatus for positioning and maintaining the position of endoscopic instruments
AU2003230805A1 (en) *	2002-04-05	2003-10-27	Penwest Pharmaceuticals Co.	Sustained release metoprolol formulations
GR1004331B (el) *	2002-10-07	2003-09-05	Verisfield (Uk) Ltd	Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
WO2006018033A1 (fr) *	2004-08-20	2006-02-23	Mepha Ag	Formulations de bisphosphonates
WO2006046100A1 (fr) *	2004-10-25	2006-05-04	Ranbaxy Laboratories Limited	Composition pharmaceutique a base d'acide alendronique
WO2006054165A1 (fr) *	2004-11-19	2006-05-26	Ranbaxy Laboratories Limited	Compositions pharmaceutiques de l'acide alendronique et leur procede de preparation
US9050391B2 (en)	2005-10-27	2015-06-09	Nexilis Ag	Implant and production method for said implant
FR2918567B1 (fr) *	2007-07-11	2012-08-03	Pf Medicament	Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
US20110229566A1 (en) *	2008-08-22	2011-09-22	Yatendra Kumar Gupta	Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
WO2010133629A1 (fr) *	2009-05-19	2010-11-25	Grindeks, A Joint Stock Company	Composition pharmaceutique stable de phosphate de fludarabine
EP2512455B8 (fr)	2009-12-18	2014-07-23	FrieslandCampina Nederland Holding B.V.	Composition d'excipient de comprimé co-traité, sa préparation et son utilisation
WO2023025672A1 (fr)	2021-08-25	2023-03-02	Basf Se	Composition auxiliaire de compression directe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5358941A (en) *	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
CZ287984B6 (cs) *	1993-05-15	2001-03-14	Roche Diagnostics Gmbh	Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby
US5853759A (en) *	1996-05-17	1998-12-29	Merck & Co.. Inc.	Effervescent alendronate formulation
EP1035869A1 (fr) *	1997-03-26	2000-09-20	Sepracor, Inc.	Formulations chimiquement et thermiquement stables de norastemizole
PL358593A1 (en) *	2000-04-07	2004-08-09	Pfizer Products Inc.	Estrogen agonist/antagonist metabolites

2000
- 2000-07-11 CZ CZ20002567A patent/CZ20002567A3/cs not_active IP Right Cessation
2001
- 2001-04-12 SK SK511-2001A patent/SK283249B6/sk not_active IP Right Cessation
- 2001-06-29 RU RU2003102448/15A patent/RU2279273C2/ru not_active IP Right Cessation
- 2001-06-29 AU AU2001270454A patent/AU2001270454A1/en not_active Abandoned
- 2001-06-29 HU HU0301072A patent/HUP0301072A3/hu unknown
- 2001-06-29 UA UA2003021190A patent/UA73784C2/uk unknown
- 2001-06-29 DE DE60121166T patent/DE60121166D1/de not_active Expired - Fee Related
- 2001-06-29 YU YU77702A patent/YU77702A/sh unknown
- 2001-06-29 US US10/257,958 patent/US7198802B2/en not_active Expired - Fee Related
- 2001-06-29 EP EP01949210A patent/EP1299088B1/fr not_active Expired - Lifetime
- 2001-06-29 WO PCT/CZ2001/000037 patent/WO2002003963A1/fr not_active Ceased
- 2001-06-29 CA CA002415630A patent/CA2415630A1/fr not_active Abandoned
- 2001-06-29 EE EEP200300017A patent/EE200300017A/xx unknown
- 2001-06-29 PL PL36087201A patent/PL360872A1/xx not_active IP Right Cessation
- 2001-06-29 HR HRP20020735 patent/HRP20020735A2/xx not_active Application Discontinuation
- 2001-06-29 AT AT01949210T patent/ATE331502T1/de not_active IP Right Cessation
2003
- 2003-02-04 BG BG107520A patent/BG107520A/bg unknown

Also Published As

Publication number	Publication date
RU2279273C2 (ru)	2006-07-10
UA73784C2 (en)	2005-09-15
DE60121166D1 (de)	2006-08-10
SK5112001A3 (en)	2002-02-05
CZ289261B6 (cs)	2001-12-12
AU2001270454A1 (en)	2002-01-21
EP1299088B1 (fr)	2006-06-28
EE200300017A (et)	2004-10-15
CA2415630A1 (fr)	2002-01-17
EP1299088A1 (fr)	2003-04-09
HUP0301072A2 (hu)	2003-08-28
CZ20002567A3 (cs)	2001-12-12
SK283249B6 (sk)	2003-04-01
YU77702A (sh)	2006-05-25
HRP20020735A2 (en)	2004-12-31
PL360872A1 (en)	2004-09-20
HUP0301072A3 (en)	2005-07-28
WO2002003963A1 (fr)	2002-01-17
US20030161878A1 (en)	2003-08-28
ATE331502T1 (de)	2006-07-15
US7198802B2 (en)	2007-04-03

Publication	Publication Date	Title
EP0861073B1 (fr)	2004-07-28	Preparations d'hormones thyroidiennes stabilisees et procede de fabrication correspondant
CA2149052C (fr)	2003-03-25	Formulations sous forme de melange sec pour acides bisphosphoniques
UA73078C2 (uk)	2005-06-15	Фармацевтичний препарат у вигляді таблеток на основі солі дихлорметилендифосфорної кислоти та силікатованої мікрокристалічної целюлози та спосіб його одержання
CZ20002391A3 (cs)	2001-11-14	Bleskově tající prostředek pro orální podání a způsob jeho výroby
JPH0660102B2 (ja)	1994-08-10	直接圧縮シクロホスファミド錠剤
IE913054A1 (en)	1992-02-25	Stabilized solid chemical compositions
US5441747A (en)	1995-08-15	Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
RU2279273C2 (ru)	2006-07-10	Таблетка, получаемая непосредственным прессованием, содержащая 4-амино-1-гидроксибутилиден-1,1-бисфосфоновую кислоту в качестве активного ингредиента
JP5719385B2 (ja)	2015-05-20	ラミプリル及びベシル酸アムロジピンの固形医薬製剤及びその製造
KR20160002177A (ko)	2016-01-07	오셀타미비어 유리염기를 포함하는 약학 조성물
CZ302157B6 (cs)	2010-11-18	Potahovaná tableta s cyklofosfamidem, zpusob její výroby a zpusob výroby tabletového jádra
US20220202839A1 (en)	2022-06-30	A solid dosage form comprising zinc gluconate and inosine pranobex, a method for its preparation and its applications
PL196485B1 (pl)	2008-01-31	Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
RU2266106C1 (ru)	2005-12-20	Способ получения антимикробного средства
KR20160140567A (ko)	2016-12-07	오셀타미비어 유리염기를 포함하는 약학 조성물
WO2026052613A1 (fr)	2026-03-12	Compositions pharmaceutiques et procédés les utilisant
KR20040090975A (ko)	2004-10-27	2,2-디클로로-12-(4-클로로페닐)-도데칸산 함유 의약 조성물